M5A-ICK

M5A-ICK is an experimental antibody-drug conjugate (ADC) that combines the humanized monoclonal antibody M5A, which targets carcinoembryonic antigen (CEA), with a cytotoxic payload via an immunoconjugate linker. The parent antibody, M5A, has been studied as a radioimmunotherapy agent when labeled with yttrium-90 for targeting CEA-expressing tumors such as colorectal cancer and medullary thyroid cancer. The ICK suffix in "M5A-ICK" typically denotes an immunocytokine or immunoconjugate format, suggesting that this molecule is designed to deliver a cytotoxic or immune-modulating payload directly to CEA-positive tumor cells. This targeted approach aims to enhance antitumor efficacy while minimizing off-target toxicity[6].